Abstract: The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and prevention of relapses of such inflammations. The invention includes also a pharmaceutical composition for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment and for prophylaxis and prevention of relapses of such inflammations, the composition containing from 75 to 95 parts by wt. of a cellulose derivative, from 0.5 to 5 parts by wt. of lactic acid, from 0.5 to 5 parts by wt. of a basic polymer, wherein the stoichiometric ratio of lactic acid to the basic polymer is comprised in the range of 1:1 to 8:1, and comprising totarol in an amount of 0.001 to 5 parts by wt. as the active substance.

Abstract: The present invention relates to novel compounds capable of activating BKCa channels. The use of a composition of the present invention can effectively activate the BKCa channels, and can be used for prevention or treatment of various diseases caused by the deactivation of BKCa channels or the degradation of BKCa channel activity.

Abstract: An organic acid salt of nicotinamide riboside (NR) is provided, where an organic acid is selected from the group consisting of malic acid, citric acid, royal jelly acid, and the like, and a molar ratio of the NR to the organic acid is 1:2 or 1:1. A compound composition of an organic acid salt of NR and a carrier is further provided, where the carrier is selected from the group consisting of niacin, glutamic acid, royal jelly acid, nervonic acid, microcrystalline cellulose (MCC), and apple cider vinegar powder. The present disclosure adopts an organic acid with strong acidity, and such an organic acid can form an intimate ion pair with NR and show some hydrophobicity, which improves the stability of NR. The carrier can prevent moisture penetration and improve the water resistance of the organic acid salt.

Abstract: The present invention provides a nanoparticle dispersion for topical delivery to skin of a mammal. The nanoparticle dispersion includes: one or more hydrophobic bioactive agents or one or more hydrophobic drugs; one or more surfactants; one or more water immiscible oils; and water. Methods of preparing nanoparticle dispersions by hot melt extrusion are also provided.

Abstract: Stabilized liquid agrochemical compositions are provided that comprise flowable, aqueous dispersion concentrates comprising a) a continuous aqueous liquid phase; b) at least one dispersed, solid phase comprising a dispersion of polymer particles having a mean particle size of at least one micron, wherein the outside surfaces of the particles comprise a colloidal solid material and wherein the particles have at least one agrochemically active ingredient distributed therein, optionally a non-porous particulate mineral that acts as a diffusion barrier to slow the release of the active ingredient, and optionally at least one non-cross-linkable mobile chemical such that the extraction of this chemical from the disperse phase renders it porous in a manner that allows the active ingredient to diffuse out. The colloidal solid is used to stabilize the polymerizable resin in an emulsion state during preparation.

Abstract: The present invention relates to a process to prepare solid pharmaceutical forms comprising a quantity of mesalazine comprised between 75 and 95%, i.e. between 1000 and 1600 mg of drug per dosage unit. Furthermore, the present invention relates to a granulate and/or tablets obtained/obtainable with the process according to the invention, preferably coated to allow the controlled release of the drug. Finally, the present invention relates to the use of the granulate and/or the tablets as a medicament, preferably for the treatment of chronic inflammatory pathologies that preferably affect the intestinal tract.

Abstract: A hetero-targeted, dual-responsive nanogel to deliver chemotherapeutic agents to a metastatic cancer is provided. The nanogel includes a first chemotherapeutic agent, a second chemotherapeutic agent, a first targeting ligand, and a second targeting ligand. A method of treating cancer in a mammal with the nanogel are also provided.

Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound in suspension, wherein the particles of the suspension are limited in size. In aspects, the compositions are stable suspensions, maintaining physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent providing both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component.

Abstract: Embodiments of the present invention pertain to antimicrobial glass compositions, glasses and articles. The articles include a glass, which may include a glass phase and a cuprite phase. In other embodiments, the glasses include as plurality of Cu1+ ions, a degradable phase including B2O3, P2O5 and K2O and a durable phase including SiO2. Other embodiments include glasses having a plurality of Cu1+ ions disposed on the surface of the glass and in the glass network and/or the glass matrix. The article may also include a polymer. The glasses and articles disclosed herein exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing condition and under Modified JIS Z 2801 for Bacteria testing conditions.

Abstract: Embodiments of the present invention pertain to antimicrobial glass compositions, glasses, and articles. The articles include a glass, which may include a glass phase and a cuprite phase. In other embodiments, the glasses include a plurality of Cu1+ ions, a degradable phase including B2O3, P2O5 and K2O, and a durable phase including SiO2. Other embodiments include glasses having a plurality of Cu1+ ions disposed on the surface of the glass and in the glass network and/or the glass matrix. The article may also include a polymer. The glasses and articles disclosed herein exhibit a 2 log reduction or greater in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, Pseudomonas aeruginosa bacteria, Methicillin Resistant Staphylococcus aureus, and E. coli, under the EPA Test Method for Efficacy of Copper Alloy as a Sanitizer testing condition and under Modified JIS Z 2801 for Bacteria testing conditions.

Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound and a suspension component comprising a polysorbate, hyaluronic acid, or both. In aspects, the compositions are stable suspensions maintaining physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions comprise a non-ionic surfactant or, e.g., a non-ionic suspension agent providing both surfactant and suspension functionality. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.

Abstract: Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.

Abstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.

Abstract: The present invention relates to the use of use of a tetrazolinone fungicide for combating phytopathogenic fungi on fruits, such fungi containing a G143A mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors.

Abstract: The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.

Abstract: Methods for removing biofilm or preventing biofilm formation from surfaces are provided, the methods comprising applying compositions to the surface to remove the biofilm or inhibit its formation, the compositions comprising polymers derived from alkyl polyglucosides functionalized with cationic side chains.

Abstract: The present invention provides a method for preparing an intravenously administrable aqueous composition comprising acetaminophen, and optionally one or more non-steroidal anti-inflammatory drugs (NSAIDs), whereby the dissolved oxygen of the composition in a closed container is maximally 1.0 ppm, said method comprises rinsing at least once a compounding vessel with water of a temperature of at least 80° C., thereby heating the vessel and creating an oxygen low environment in said vessel; and in said rinsed vessel dissolving acetaminophen in water for injection, said water for injection is at a temperature of at least 80° C., whereby optionally one or more NSAIDS are added prior or after dissolving of acetaminophen.

Abstract: Compositions and methods are presented that provide substantially improved physical and pharmacological parameters for subungually administrable formulations. Most beneficially, the compositions presented herein have a viscosity and film-forming capacity that retain the liquid formulation in sufficient quantities and that help penetrate the polysaccharide matrix commonly associated with onychomycosis. In especially preferred aspects, the carrier is formulated to have a high concentration of the active pharmaceutically active agent (API), to allow migration of the formulation within the subungual space, and to reduce systemic absorption while promoting diffusion of the API into the nail plate at or above minimum inhibitory concentration into a larger treatment space.

Abstract: There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.